cecilie_arcurs / iStockphoto.com
Gilead Sciences is to acquire Kite Pharma for $11.9 billion, after the deal was unanimously approved by both companies’ boards of directors.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gilead Sciences, Kite Pharma, M&A, mergers and acquisitions, FDA, axicabtagene ciloeucel (axi-cel), CAR T therapy